Last reviewed · How we verify
NCT05896020
A Study of SHR-A1811 in Subjects With Gynaecologic Oncology
Phase 2 trial testing SHR- A1811 in Gynaecological Malignancies in 225 participants. Currently enrolling.
15 June 2026
Quick facts
| Lead sponsor | Jiangsu HengRui Medicine Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 225 |
| Start date | 10 July 2023 |
| Primary completion | 15 June 2026 |
| Estimated completion | 15 June 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- SHR- A1811
Conditions studied
- Gynaecological Malignancies — all drugs for Gynaecological Malignancies →
Sponsor
Jiangsu HengRui Medicine Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, female only, with Gynaecological Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, two-part study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with a gynaecological malignancies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer.
Sato S, Shoji T, Jo A, Otsuka H, et al · · 2024 · cited 10× · PMID 39061184 · DOI 10.3390/cancers16142545
Verify or expand the search:
- PubMed search for NCT05896020
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SHR- A1811
Trials testing the same drug.
- NCT07307287 — SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: · Phase 2 · not yet recruiting
- NCT07047443 — SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression · Phase 2 · not yet recruiting
Other recruiting trials for Gynaecological Malignancies
Currently open trials in the same condition.
- NCT07210164 — Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study · NA · recruiting
Other Jiangsu HengRui Medicine Co., Ltd. trials
Trials by the same sponsor.
- NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
- NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
- NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
- NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
- NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05896020 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
- Last refreshed: 22 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05896020.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing